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INTRODUCTION: Medullary thyroid carcinoma may occur in a sporadic (s-medullary thyroid carcinoma, 75%) or in a multiple 
endocrine neoplasia type 2 form (MEN2, 25%). These clinical forms differ in many ways, as s-medullary thyroid carcinoma cases 
are RET-negative in the germline and are typically diagnosed later than medullary thyroid carcinoma in MEN2 patients. In this 
study, a set of cases with s-medullary thyroid carcinoma are documented and explored. 
PURPOSE: To document the phenotypes observed in s-medullary thyroid carcinoma cases from a university group and to attempt 
to improve earlier diagnosis of s-medullary thyroid carcinoma. Some procedures for diagnostics are also recommended.
METHOD: Patients (n=26) with apparent s-medullary thyroid carcinoma were studied. Their clinical data were reviewed and 
peripheral blood was collected and screened for RET germline mutations.
RESULTS: The average age at diagnosis was 43.9 years (± 10.82 SD) and did not differ between males and females. Calcitonin 
levels were increased in all cases. Three patients presented values that were 100-fold greater than the normal upper limit. Most 
(61.54%) had values that were 20-fold below this limit. Carcinoembryonic antigen levels were high in 70.6% of cases. There was 
no significant association between age at diagnosis, basal calcitonin levels or time of disease onset with thyroid tumor size (0.6-15 
cm). Routine thyroid cytology yielded disappointing diagnostic accuracy (46.7%) in this set of cases. After total thyroidectomy 
associated with extensive cervical lymph node resection, calcitonin values remained lower than 5 pg/mL for at least 12 months 
in eight of the cases (30.8%). Immunocyto- and histochemistry for calcitonin were positive in all analyzed cases. None of the 26 
cases presented germline mutations in the classical hotspots of the RET proto-oncogene. 
CONCLUSION: Our cases were identified late. The basal calcitonin measurements and immunostaining for calcitonin were highly 
useful for diagnosing s-medullary thyroid carcinoma. The rate of complete patient recovery was low, and none of the parameters 
analyzed were useful predictors of the thyroid tumor size. Our findings support previous recommendations for routine serum cal-
citonin evaluation and immunostaining analysis involving single thyroid nodules. 
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INTRODUCTION
Medullary thyroid carcinoma (MTC) is a rare 
neuroendocrine tumor derived from the parafollicular C-cells 
that secrete calcitonin. It represents 4%-5% of all thyroid 
cancers1,2 and is prevalent in 0.57%-1.37% of thyroid nodular 
diseases.3-7 Most MTCs occur in a sporadic form (s-MTC), 
whereas 25%-30% are inherited as the predominant 
component of multiple endocrine neoplasia type 2 (MEN2) 
syndromes MEN2A, MEN2B and familial MTC.8 In MEN2, 
MTC is caused by activating germline mutations in the 
RET proto-oncogene, which is located at chromosome 10 
(10q11.2), and encodes a receptor protein tyrosine kinase 
known as the RET receptor.9 All cases with MTC, with or 
without a clear family history of the disease, should be 
submitted for RET mutation analysis. Approximately 7% of 
the cases with apparent s-MTC harbor a germline mutation, 
and are therefore indeed familial cases. Furthermore, many 
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s-MTC cases may present with thyroid somatic mutations, 
mostly in RET codon 918.10-11
The sporadic form of MTC is defined by the absence of 
a familial history for MTC as well as a lack of RET germline 
mutations and other MEN2A-related tumors. Patients 
with s-MTC are usually diagnosed late during physical 
examination by the identification of a solitary thyroid nodule, 
which is typically observed in patients in their 40´s and 50´s 
and detected by either high serum levels of calcitonin, 
cytology from fine needle thyroid biopsy (preferentially with 
immunostaining for calcitonin) or both. It presents with a 
slow growth and spreads quickly to regional cervical lymph 
nodes. At the time of diagnosis, up to 70% of cases may 
present with local cervical metastasis. A distant metastasis 
may occur mainly in the liver, lung, bone and brain.12 The 
only effective treatment for MTC is surgery, as it is usually 
resistant to conventional chemo- or radiotherapy.13-17 New 
therapies for MTC, which are being tested in clinical trials, 
are mostly novel targeting chemotherapies18. The outcome of 
s-MTC depends on the extent of the disease, nature of tumor 
biology and efficacy of surgical treatment. In general, a 10-
year survival rate of 60%–70% is observed.19 
In the sporadic form, MTC differs from the MTC in 
MEN2 in many ways: 1) it has a later disease onset and 
is associated with later diagnoses, 2) it is usually less 
aggressive, 3) the thyroid nodule is unilateral and unicentric, 
4) there exists no other associated MEN2-neoplasia, 5) 
it lacks a germline mutation in the RET proto-oncogene, 
and 6) family members are not affected by the disease. 
Although RET mutation analysis of at-risk family members 
currently allows for early diagnosis in MEN2, the positive 
identification of s-MTC is usually performed late, which 
leads to a low surgical and biochemical “cure” (i.e., 
calcitonin < 5 pg/mL for at least 12 months). 
Calcitonin is a highly sensitive biochemical marker 
for MTC; however, it has a lower specificity. Thus, 
hypercalcitoninemia may also be related to the use of drugs 
such as omeprazole. It may also be related to diseases such 
as autoimmune thyroiditis or other thyroid tumors, such as 
papillary thyroid carcinoma (PTC) and follicular thyroid 
tumor (FTC), renal insufficiency, neuroendocrine tumors and 
C-cell hyperplasia.20-23 
The early diagnosis of s-MTC remains a challenge. 
Most investigators agree that routine measurements of 
serum calcitonin in all cases with thyroid nodules may 
substantially increase the rates of early diagnosis and cure 
for s-MTC.4-7,23-25 Furthermore, increased levels of calcitonin 
are often the only indicator of MTC at early stages of 
the disease.26 This procedure, however, is not advocated 
worldwide.27 
We therefore decided to retrospectively investigate 
cases with MTC but without associated familial history as 
identified by our facility over the past 26 years. A number of 
these patients were primarily followed by other institutions 
and then referred to our unit for treatment. Clinical data, 
calcitonin values, thyroid biopsies, imaging studies 
and pathological findings were recorded, reviewed and 
statistically analyzed. 
MATERIALS AND METHODS
Subjects: We reviewed the clinical and familial 
histories of 26 patients with apparent s-MTC but without 
associated familial history. All patients were followed by 
our group at the Genetic Endocrinology Unit, Department 
of Endocrinology, at the Hospital das Clínicas (University of 
São Paulo School of Medicine). The time of MTC incidence 
was estimated from the interval between the appearance 
of the thyroid nodule and admission for surgery. Over the 
past few years, serum calcitonin values have been measured 
using three different assays: 1) a radioimmunoassay 
commercial kit (RIA) (Diagnostics Product Corporation- 
DPC, USA) in which the upper normal value is 50 pg/mL 
2) an immunoradiometric assay (IRMA) (Cisbio Bioassays 
International-CISBIO, France) with an upper normal value 
of 10pg/mL and 3) since 2002, a commercial automated 
chemiluminescent immunoassay kit (Diagnostics Product 
Corporation- DPC IMMULITE®, USA) with normal values 
for men of up to 8.4 pg/mL and for women of up to 5.0 
pg/mL. We performed routine biochemical exams using 
typical automated methods. Thyroid-stimulating hormone 
(TSH) was measured by immunofluorometric assay (IFMA) 
(Wallac, Auto-Delphia, Perkin Elmer, Turku, Finland), with 
normal values ranging from 0.3 to 4.5 µU/mL. Free-T4 
was measured by fluoroimmunoassay (FIA) (Wallac, Auto-
Delphia, Perkin Elmer, Turku, Finland), with normal values 
ranging from 0.7 to 1.5 ng/dL. Finally, CEA was measured 
between 1982 and 2000 by enzyme immunoassay (EIA) and 
between 2001 and 2006 by chemiluminescence immunoassay 
(Diagnostics Product Corporation- DPC IMMULITE®, 
USA), with normal values for non-smokers of up to 5.0 
ng/mL and for smokers of up to 10.0 ng/mL. Thyroid 
ultrasounds and fine needle biopsies were performed using 
routine methods. Immunocyto- and immunohistochemical 
reactions for calcitonin were performed by our institution’s 
pathology department as previously reported.28 The sizes 
of the thyroid nodules were estimated in centimeters by 
ultrasound and/or by pathological measurements. 
DNA extraction: Peripheral blood was collected from 
all patients and screened for RET mutations as previously 
reported.29-32 All patients signed an informed consent form 
before their blood was collected.
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Statistical analysis: Descriptive analyses were given 
for all variables. Medians for calcitonin and CEA were 
calculated, as these values were not normally distributed. 
Statistical assessments included the Pearson correlation 
coefficient, the Student’s t-test and the Mann-Whitney test. 
A p value of less than 0.05 was regarded as statistically 
significant. All analyses were performed using the STATA 
8.0 statistical software.
This project was submitted and approved by the Ethical 
Committee of Hospital das Clínicas da Faculdade de 
Medicina da Universidade de São Paulo (CAPPesq) and the 
National Council of Ethics (CONEP).
RESULTS
Clinical data
Age
A total of 26 patients followed from 1982-2006 with the 
diagnosis of apparent s-MTC were enrolled in this study 
(Table 1). The average age at diagnosis was 43.9 ± 10.82 
years, and no gender differences were observed (males, 
47.08 ± 11.62; females, 42.04 ± 10.18; p=0.25) (Table 1). 
Thyroid nodules
The vast majority of patients (92.3%) had a clinical 
history of a single thyroid nodules and most (65.4%) stated 
that they had felt something unusual 1-5 years before 
diagnosis. Two patients did not have a history and did not 
exhibit palpable nodules at the time of diagnosis. All levels 
of TSH and free-T4 were within normal limits. 
Cervical metastasis
Cervical ultrasound data from 18 cases showed enlarged 
lymph nodes compatible with local metastases in nine cases 
(50%). Pathological data were recovered from 26 cases, and 
MTC cervical lymph nodes metastases were documented in 
10 cases (38.5%).
Table 1 - Clinical and biochemical data for the 26 patients
Case Gender History of Thyroid 
nodule 
(yr)
Age at 
diagnosis 
(yr)
TSH 
(µU/mL)
free T4 
(ng/dL)
CEA 
(ng/mL)
Calcitonin 
(pg/mL)
Calcitonin 
Method**
Fold 
Increase***
1 M 0.7 44 3.4 1.0 139.5 220.0 B 7.3
2 M 1.0 57 16.3 937.3 B 18.7
3 M 1.0 33 0.3 40.0 C 8.7
4 M 4.0 30 1.1 1.0 100.0 1063.3 B 21.3
5 F 1.0 43 2.8 1.2 40.0 422.5 A 8.4
6 F N.H.* 47 1.0 1.0 7.0 625.0 B 12.5
7 F 5.0 25 1.8 19.0 C 4.1
8 F 4.0 40 0.7 1.0 6.4 56.5 A 1.1
9 F 3.0 38 1.0 1.1 24.7 22.4 B 0.4
10 M 0.8 57 2.9 1.0 - 4170.0 C 362.6
11 F 1.0 17 2.4 1.2 9.8 990.0 B 19.8
12 M 20.0 61 3.2 1.2 - 1500.0 A 25.0
13 F 1.0 53 10.0 350.0 B 70.0
14 F 4.0 43 1.6 1.1 2.7 873.0 B 17.5
15 M 0.8 42 1.9 1.0 45.0 335.0 B 18.6
16 F 8.0 46 59.9 630.0 C 12.6
17 F 0.7 40 2.2 1.2 32.8 1630.0 C 326.0
18 F 4.0 50 2.5 1.3 87.7 3135.5 B 627.1
19 F 1.0 42 1.5 1.2 1.5 107.3 A 2.1
20 M 1.0 41 1.4 1.3 5.5 50.0 B 1.7
21 M 0.5 42 3.3 1.0 1.5 71.0 A 2.7
22 F 1.0 61 1.7 1.1 15.6 1435.6 B 47.9
23 F 5.0 40 1.6 1.0 36.8 2411.0 B 48.2
24 M N.H.* 63 0.7 1.0 100.0 1401.0 A 46.7
25 F 2.0 47 1.2 1.1 46.6 326.0 C 70.9
26 F 1.0 41 3.1 1.2 2.0 97.0 C 19.4
* N.H. No history at the time of diagnosis. ** A=radioimmunoassay (RIA), B=immunoradiometric assay (IRMA), C= chemiluminescent immunoassay. 
*** Calcitonin value fold increase over normal according to the method used.
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Calcitonin and CEA values
Basal calcitonin levels were high at the time of diagnosis 
and ranged from 19.0 to 4,170.0 pg/mL. Since part of this 
wide range could be explained by the fact that the three 
methods used had different normal values for calcitonin, we 
calculated how many times it was above the upper normal 
limit for each patient. Three patients presented with values 
that were 100-fold greater than the normal upper limit. Most 
of the patients (61.54%) exhibited values that were 20-fold 
below this level. There were no differences in calcitonin values 
between genders (p=0.99). As listed in Table 1, the variability 
across subjects remained, and it was not possible to identify 
a potential factor that would explain this phenomenon using 
time of disease, age at diagnosis, size of the tumor, or presence 
of metastases at the time of diagnosis as prognostic factors. 
Levels of CEA were abnormally high in 17 (70.8%) of the 24 
cases (median, 15.9 ng/mL; SD, 38.6) (Table 1).
Thyroid tumor size
The thyroid tumor size, estimated by either ultrasound 
and/or pathological data in 26 cases, varied from 0.6 to 15 cm 
(Table 2). To estimate the possible correlation of the tumor size 
with calcitonin levels, duration of the disease and the outcome 
(cure/no cure), we separated the tumor size into smaller than 
1 cm and larger than 1 cm diameter categories. We found no 
differences between the two groups. We then created another 
category, separating tumor size into three groups - up to 1 cm, 
between 1.1 and 1.4 cm, and larger than 1.5 cm. Again, no 
significant difference was observed (p > 0.05). 
Association
The Pearson’s correlation test was employed to test for 
linear associations between two variables. A Student’s t-test 
was used to evaluate the differences in means between the 
two groups. There was no significant difference in calcitonin 
or CEA levels among the categories of thyroid nodule size in 
our patients (p > 0.05). Furthermore, there was no significant 
correlation between the time since diagnosis and the age 
at diagnosis with serum calcitonin levels, CEA or thyroid 
tumor sizes. Although males with MTC tended to be older 
than affected females at diagnosis, no significant differences 
were observed (p=0.25). Basal calcitonin levels presented a 
wide range of variation in these cases, but this variation did 
not differ between males and females (p=0.99). Levels of 
CEA were higher in cases with more extensive metastases, 
but these differences were not significant (p=0.12). 
Pathologic data
Cytological data
Cytological analyses performed on thyroid samples 
obtained through fine needle biopsies of the thyroid nodules 
were recovered for 15 (57.7%) patients and were consistent 
with MTC in seven of those cases (46.7%). Papillary 
thyroid carcinoma (PTC) was found in two cases, mixed 
PTC and MTC in one case, follicular thyroid tumor (FTC) 
in two cases and a Riedel tumor in one. Thus, in eight 
cases, the cytological finding per se was inconsistent with 
an MTC diagnosis. Using routine analysis techniques, 
immunocytochemical staining was performed in 3 of the 
15 cytologically studied cases (20.0%). All reactions were 
markedly positive for calcitonin (Table 2). 
Histopathological findings
Data from pathological analyses were recovered in 
all cases. The diagnoses were compatible with MTC 
in all patients with 100% accuracy. One case presented 
with a mixed medullary/papillary thyroid tumor. 
Immunohistochemical analysis was performed in 11 cases 
(42.3%). All reactions were strongly positive for calcitonin, 
which was compatible with MTC (Table 2).
Post-surgical follow-up
Twelve patients (46.2%) were thyroidectomized in 
other institutions prior to follow up by our group. A total 
thyroidectomy and central and bilateral neck dissection 
(levels II to VII) was performed in the other 14 s-MTC 
patients using a previously described surgical approach.33 
There was no difference in calcitonin levels, time of disease 
or size of thyroid nodules between these two groups. Eight 
patients (30.8%) presented with post-surgical calcitonin 
levels lower than 5 pg/mL for at least 12 months after 
surgery. These cases were initially classified as biochemically 
relapsed. One patient was considered inoperable and died 
soon after diagnosis (case 10) (3.9%), and 17 cases (65.4%) 
were not biochemically cured. No differences were observed 
in tumor size, time of disease, age at diagnosis, or calcitonin 
levels between the group that was classified as biochemically 
relapsed and the group that was not. 
RET mutation analysis
No RET germline mutations were identified in any of the 
26 cases, confirming the presence of the sporadic form of 
MTC in all patients.
DISCUSSION 
In modern molecular medicine, genetic screening is an 
increasingly useful tool35 that is currently applied to inherited 
tumor syndromes such as multiple endocrine neoplasia types 
136 and 2.31
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A routine search for RET germline mutations in all 
cases that presented with MTC and/or pheochromocytoma 
and in at-risk family members from MEN2 genealogies 
is recommended worldwide and is frequently performed 
in Brazil.30-32 This procedure has been critical in the early 
detection of RET mutation carriers and has prompted the 
recommendation of prophylactic total thyroidectomy in 
the case of younger RET-positive carriers.10 This may 
dramatically modify the outcome of MTC in MEN2 and 
may lead to a definitive surgical and biochemical cure 
of this disease in younger, asymptomatic RET-positive 
carriers.9,10,12
The early recognition of s-MTC cases, however, remains 
a challenge. The diagnosis of s-MTC is usually late and is 
performed only when a thyroid nodule is already detectable 
either by ultrasound (frequently with diameters from 0.2 
to 0.9 cm) or by palpation (> 1.0 cm). At this latter stage, 
cervical metastases are often already present (50%-70%). 
Furthermore, research has shown that MTC tumors with a 
diameter of 1.0 cm may have been growing for 3-4 years.3 
At diagnosis, basal calcitonin levels are high in almost all 
s-MTC cases, a finding which is certainly expressed by 
our data. Cytological data obtained from thyroid biopsies, 
however, may not be associated with good rates of diagnostic 
accuracy, as observed in our study. Often on account of 
late diagnoses, persistent biochemical cure after the first 
thyroid surgery or reoperation is only achieved in ~30% of 
the cases,38 similar to the apparent rate of biochemical cure 
(30.8%) observed in the present cases. 
In attempting to improve the early diagnosis of 
s-MTC, several authors have recommended routine 
serum calcitonin measurements in all cases with thyroid 
Table 2 - Cytological and pathological data from the 26 patients
Case Nodule size (cm) Fine needle biopsy Pathological data Cure
Results1 ICC2 Results1 IHC2
1 6.0 PTC/MTC - MTC - yes
2 1.0 - - MTC positive no
3 2.5 - - MTC positive yes
4 1.0 MTC positive MTC - no
5 8.0 PTC positive PTC/MTC - no
6 1.0 negative - MTC - no
7 9.0 PTC - MTC positive yes
8 2.0 - - MTC positive yes
9 3.0 MTC positive MTC positive yes
10 15.0 MTC - MTC - death
11 2.1 FTC - MTC positive no
12 12.0 - - MTC - no
13 1.3 - - MTC - no
14 6.0 neoplasia - MTC - no
15 0.6 Riedel - MTC - no
16 4.3 - - MTC positive no
17 4.8 - - MTC - yes
18 3.0 MTC - MTC positive no
19 3.0 - - MTC - no
20 4.2 - - MTC positive no
21 2.0 - - MTC positive no
22 4.0 MTC - MTC - no
23 1.3 MTC - MTC positive no
24 1.0 - - MTC - no
25 2.5 MTC - MTC - yes
26 0.8  neoplasia - MTC - yes
1PTC = papillary thyroid carcinoma; MTC = medullary thyroid carcinoma; FTC = follicular thyroid carcinoma; 2 ICC = immunocytochemistry; 3IHC = 
immunohistochemistry
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nodule disease.5-7,23-25,34 This procedure has primarily been 
suggested by European investigators since 1994 and has 
been supported by several other studies.5-7 In Brazil, it has 
been recommended that a systematic approach of single solid 
thyroid nodule be employed by means of routine evaluation 
of basal calcitonin values.34 Others have also recommended 
this procedure.37 Up to 1.4% of previously unsuspected 
MTC cases have been reported in unselected sequential 
cases presenting with thyroid nodules.23 Furthermore, the 
cost benefits of routine calcitonin measurements and of 
therapeutic procedures have recently been evaluated. In 
cases with local and advanced metastases, the data favored 
the procedure.23 It is worth noting that MTC is usually 
resistant to conventional chemo- and radiotherapy, which 
motivates the need for the early detection of this condition. 
This management for thyroid nodules, however, has not been 
recommended worldwide.27 
We documented consistently high basal levels of 
calcitonin in all 26 s-MTC patients, confirming that this 
serum marker is very sensitive for biochemical diagnosis. 
A cohort study24 showed that MTC was confirmed in 
almost all patients with thyroid nodules associated with 
calcitonin values higher than 100 pg/ml. Thus, this cut-off 
point for basal calcitonin levels has been frequently used to 
discriminate between cases with and without MTC.26 
In our sample, age at diagnosis, calcitonin levels and 
time of disease were not associated with the thyroid tumor 
size, consistent with previous suggestions.13 These findings 
indicate that these parameters may not be accurate predictors 
of MTC outcomes in our specific sample. 
In our study, post-surgical follow-up was performed in 24 
MTC cases (92.3%). Persistently low levels of calcitonin (< 
5 pg/mL) after thyroid surgery were present in eight patients 
(30.8%). This relatively low rate of surgical success suggests 
a late diagnosis of MTC in our cases. Similar apparent 
biochemical cure rates (33%) have been reported by others.13 
Our institution currently recommends that patients diagnosed 
late with s-MTC should undergo a total thyroidectomy, 
central and bilateral neck dissection (levels II to VII) as well 
as a thymectomy and resection of the thymic lymph nodes.33 
This latter procedure appears to increase the surgical success 
rate in MTC (Tavares, MR – unpublished data).
In our cases, pathologic data were compatible with 
MTC in all 26 patients. Immunohistochemical analysis 
was performed in nearly half of the cases and the new data 
reinforced the MTC diagnosis on every occasion. Conversely, 
when applied to the present cases, thyroid cytology exhibited 
a low accuracy (46.7%). Given the small number of biopsies 
that were recovered (57.7%), the lower accuracy rate 
may be due to information bias. One must also consider 
the fact that only 20% of the fine needle biopsies were 
complemented by immunocytochemical reactions (ICC). In 
our sample, immunocytochemical staining was indicative 
of MTC in all analyzed cases, including one thyroid 
cytology that was diagnosed as PTC. Immunocytochemical 
analysis may therefore increase the accuracy of the fine 
needle biopsy procedure. The diagnosis of MTC, which 
is essential for both the surgical approach to the primary 
tumor and for related patient management, should rely not 
only on thyroid cytology but should also take into account 
immunocytochemical reactions. It is also worth noting that 
thyroid cytology may occasionally fail to present with a 
sufficient number of cells to permit an adequate cytological 
examination. 
These findings suggest that immunocyto- and/or 
immunohistochemical reactions to calcitonin should be 
routinely performed in all cases of suspected MTC to 
improve the early recognition of this neoplasia.
Finally, the systematic mutation analysis of the six RET 
proto-oncogene hot-spot exons applied to our 26 patients 
allowed us to confirm the presence of the sporadic form of 
MTC (Toledo RA et al., unpublished data). 
Data from this specific set of s-MTC cases have 
given further support to the recommendation that serum 
calcitonin measurements should be performed in all 
patients who present with thyroid nodules in an attempt 
to diagnose s-MTC at earlier stages. It would also be 
advisable for clinicians to routinely ask for immunocyto- 
and histochemical reactions to calcitonin in all cases where 
suspected thyroid nodules present in the context of MTC. 
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